Allogene Therapeutics Inc... (ALLO)
| Bid | 1.2 |
| Market Cap | 269.04M |
| Revenue (ttm) | -22K |
| Net Income (ttm) | -252.32M |
| EPS (ttm) | -1.22 |
| PE Ratio (ttm) | -1.01 |
| Forward PE | -1.24 |
| Analyst | Buy |
| Ask | 1.21 |
| Volume | 1,486,079 |
| Avg. Volume (20D) | 3,084,790 |
| Open | 1.20 |
| Previous Close | 1.23 |
| Day's Range | 1.18 - 1.26 |
| 52-Week Range | 0.86 - 3.78 |
| Beta | 0.31 |
About ALLO
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for ALLO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
1 week ago · https://www.defenseworld.net
Squarepoint Ops LLC Sells 168,152 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)Squarepoint Ops LLC cut its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 89.2% during the fourth quarter, according to the company in its most recent disclosu...
3 weeks ago · seekingalpha.com
Allogene Therapeutics: Buying Around A Potential ASCO Lazarus MomentAllogene's off-the-shelf CAR-T therapies offer scalable, rapid solutions with a diversified pipeline targeting hematologic malignancies, solid tumors, and autoimmune diseases. Upcoming ASCO data, espe...
1 month ago · seekingalpha.com
Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call TranscriptAllogene Therapeutics, Inc. (NASDAQ:ALLO ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer Davi...
